KR910009688A - 광색성 화합물,이의 제조방법 및 용도 - Google Patents

광색성 화합물,이의 제조방법 및 용도 Download PDF

Info

Publication number
KR910009688A
KR910009688A KR1019900019252A KR900019252A KR910009688A KR 910009688 A KR910009688 A KR 910009688A KR 1019900019252 A KR1019900019252 A KR 1019900019252A KR 900019252 A KR900019252 A KR 900019252A KR 910009688 A KR910009688 A KR 910009688A
Authority
KR
South Korea
Prior art keywords
alkyl
hydrogen
phenyl
benzyl
substituted
Prior art date
Application number
KR1019900019252A
Other languages
English (en)
Inventor
피셔 에벨린
피셔 발터
핀터 위르겐
마이어 쿠르트
로트 마르틴
Original Assignee
베르너 발데크
시바-가이기 에이지
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 베르너 발데크, 시바-가이기 에이지 filed Critical 베르너 발데크
Publication of KR910009688A publication Critical patent/KR910009688A/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D335/00—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom
    • C07D335/04—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D335/10—Dibenzothiopyrans; Hydrogenated dibenzothiopyrans
    • C07D335/12—Thioxanthenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D219/00—Heterocyclic compounds containing acridine or hydrogenated acridine ring systems
    • C07D219/04—Heterocyclic compounds containing acridine or hydrogenated acridine ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
    • C07D219/06—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/78—Ring systems having three or more relevant rings
    • C07D311/80—Dibenzopyrans; Hydrogenated dibenzopyrans
    • C07D311/82—Xanthenes
    • C07D311/84—Xanthenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 9
    • C07D311/86—Oxygen atoms, e.g. xanthones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D335/00—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom
    • C07D335/04—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D335/10—Dibenzothiopyrans; Hydrogenated dibenzothiopyrans
    • C07D335/12—Thioxanthenes
    • C07D335/14—Thioxanthenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 9
    • C07D335/16—Oxygen atoms, e.g. thioxanthones
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
    • C09K9/00—Tenebrescent materials, i.e. materials for which the range of wavelengths for energy absorption is changed as a result of excitation by some form of energy
    • C09K9/02—Organic tenebrescent materials
    • G—PHYSICS
    • G03—PHOTOGRAPHY; CINEMATOGRAPHY; ANALOGOUS TECHNIQUES USING WAVES OTHER THAN OPTICAL WAVES; ELECTROGRAPHY; HOLOGRAPHY
    • G03F—PHOTOMECHANICAL PRODUCTION OF TEXTURED OR PATTERNED SURFACES, e.g. FOR PRINTING, FOR PROCESSING OF SEMICONDUCTOR DEVICES; MATERIALS THEREFOR; ORIGINALS THEREFOR; APPARATUS SPECIALLY ADAPTED THEREFOR
    • G03F7/00—Photomechanical, e.g. photolithographic, production of textured or patterned surfaces, e.g. printing surfaces; Materials therefor, e.g. comprising photoresists; Apparatus specially adapted therefor
    • G03F7/004—Photosensitive materials
    • G03F7/027—Non-macromolecular photopolymerisable compounds having carbon-to-carbon double bonds, e.g. ethylenic compounds
    • G03F7/028—Non-macromolecular photopolymerisable compounds having carbon-to-carbon double bonds, e.g. ethylenic compounds with photosensitivity-increasing substances, e.g. photoinitiators
    • G03F7/031—Organic compounds not covered by group G03F7/029
    • G—PHYSICS
    • G03—PHOTOGRAPHY; CINEMATOGRAPHY; ANALOGOUS TECHNIQUES USING WAVES OTHER THAN OPTICAL WAVES; ELECTROGRAPHY; HOLOGRAPHY
    • G03F—PHOTOMECHANICAL PRODUCTION OF TEXTURED OR PATTERNED SURFACES, e.g. FOR PRINTING, FOR PROCESSING OF SEMICONDUCTOR DEVICES; MATERIALS THEREFOR; ORIGINALS THEREFOR; APPARATUS SPECIALLY ADAPTED THEREFOR
    • G03F7/00—Photomechanical, e.g. photolithographic, production of textured or patterned surfaces, e.g. printing surfaces; Materials therefor, e.g. comprising photoresists; Apparatus specially adapted therefor
    • G03F7/004—Photosensitive materials
    • G03F7/038—Macromolecular compounds which are rendered insoluble or differentially wettable
    • G03F7/0388—Macromolecular compounds which are rendered insoluble or differentially wettable with ethylenic or acetylenic bands in the side chains of the photopolymer
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S430/00—Radiation imagery chemistry: process, composition, or product thereof
    • Y10S430/163—Radiation-chromic compound

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • General Physics & Mathematics (AREA)
  • Materials Engineering (AREA)
  • Engineering & Computer Science (AREA)
  • Polymerisation Methods In General (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Materials For Photolithography (AREA)

Abstract

내용 없음

Description

광색성 화합물, 이의 제조방법 및 용도
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (23)

1-펜옥시-4-메틸크산텐-9-온을 제외한 일반식(Ⅰ)의 화합물.
상기식에서, X는 O, S, SO, SO2또는 NR13이고, R1내지 R5는 각각 독립적으로 수소, C1-C12알킬, C1-C12알콕시, C1-C12알킬티오, C1-C4알킬-SO-, C1-C4알킬-SO2-, 할로겐, -CF3, -CN, -NO2, -OH, -COOR14, -CON(R15)2, 또는 -N(R15)2또는 일반식
(여기서, R16및 R17은 각각 독립적으로 C1-C6알킬, 페닐, C1-C6알킬페닐 또는 (C1-C6알킬)2-페닐이다)의 라디칼이거나, R3 및R4또는 R4및 R5각각은 함께 -CH=CH-CH=CH-를 형성하고;R6내지 R12는 각각 독립적으로 수소, C1-C12알킬, C1-C12알콕시, C1-C12알킬티오, C1-C12알킬-SO-, C1-C12알킬-SO2-, 벤질 또는 1 또는 2개의 -CN 및/또는 -COOR14에 의해 1-치환된 C1-C4알크-1-일, C6-C10아릴, C7-C14알랄킬, C6-C10아릴-CO, C6-C10아릴옥시, C6-C10아릴티오, C6-C10아릴-SO3-, C6-C10아릴-CO, C6-C10아릴옥시, C6-C10아릴-SO2, C7-C14아랄킬옥시, C7-C14아랄킬티오, C7-C14아랄킬-SO-, C7-C14아랄킬, C7-C14아랄킬-SO-, C7-C14아랄-SO2-, C1-C18아실-O-, -COOR14, -CON(R15)2, C1-C18아실-NR15-, (R15)2N-, 할로겐, -CF3또는 -CN이거나, R6내지 R12중 두개의 인접한 라디칼 각각은 그룹 -CO-O-CO- 또는 -CO-NR13-CO-이며, 이때 아릴 라디칼 및 아릴 그룹을 함유하는 라디칼은 할로겐, -CN, -CF3, C1-C6알킬티오, C1-C6알콕시, C1-C6알킬, -COOR14, -CO-N(R15)2또는 C1-C12알실-O-에 의해 치환되고, R13은 수소, C1-C12알킬 또는 C1-C12아실, 비치환되거나, C1-C6알킬, C1-C6알콕시, C1-C6알킬티오, 할로겐 또는 -COOR14에 의해 치환된 페닐 또는 벤질이고, 두개의 R15는 함께 C4-C6알킬렌, 3-옥시-1,5-페틸렌, 3-티아-1,5-펜틸렌, 1,3-부타디엔-1,4-디일 또는 2-아자-1,3-부타디엔-1,4-디일이거나, R15라디칼은 각각 독립적으로 수소, C1-C12알킬 또는 비치환되거나, C1-C6알킬, C1-C6알콕시, C1-C6알킬티오, 할로겐 또는 -COOR14에 의해 치환된 페닐 또는 벤질이며, R14는 수소 또는 OH그룹이 떨어져나간 방향족 또는 지방족 알코올이다.
제1항에 있어서, 일반식(Ⅰ)에서 R1내지 R5가 각각 독립적으로 수소, C1-C6알킬, C1-C6알콕시, 할로겐, CF3, -CN, -NO2, -COOR14, -OH 또는 -N(R15)2이거나, R3및 R4또는 R4및 R5가 각각 함께 -CH=CH-CH=CH-을 나타내고, R15는 각각은 C1-C6알킬이며, R14가 직쇄 또는 측쇄 C1-C18알킬인 화합물.
제2항에 있어서, 일반식(Ⅰ)에서 라디칼 R1내지 R5중의 2개 이상의 수소인 화합물.
제1항에 있어서, 일반식(I)에서 R6내지 R12는 각각 독립적으로 수소, C1-C6알킬, C1-C6알콕시, C1-C6알킬티오, C1-C6알킬-SO-, C1-C6알킬-SO2-, 1 또는 2개의 -CN 및/또는 -COOR14에 의해 1-치환된 C1- 또는 C2알킬, 페닐, 페닐-C1-C4알킬렌, 페닐-CO-, 페닐옥시, 페닐티오, 페닐-SO-, 페닐-SO2-, 벤질옥시, 벤질티오, 벤질-SO-, 벤질-SO2-, C1-C8아실-NR15-, -COOR14, -CO-N(R15)2, (R15)2N-, -T, -Cl, -Br, -CF3또는 -CN이거나, 두개의 인접한 R6내지 R12라디칼 각각은 함께 -CO-O-CO- 또는 -CO-NR13-CO-를 나타내며, R13이 C1-C6알킬 또는 비치환되거나, C1-C4알킬, C1-C4알콕시, F,Cl,Br 또는 -COOR14에 의해 치환된 페닐 또는 벤질이고, 두개의 R14는 수소, 직쇄 또는 측쇄 함께 C1-C16알킬, 페닐, 벤질 또는 (CnH-O)mR18(여기서, n은 정수 2 내지 6이고, m은 1 내지 20이며, R18은 수소, C1-C16알킬, 사이클로헥실, 페닐 또는 벤질이다)이며, R15,가 C1-C6알킬 또는 비치환되거나, C1-C4알킬, C1-C4알콕시, -F, -Cl, -Br 또는 -COOR14에 의해 치환된 페닐 또는 벤질이거나, 두개의 R15라디칼이 함께 1,4-부틸렌, 1,5-펜틸렌, 3-옥시-1,5-펜틸렌, 또는 1,3-부타디엔-1,4-디일인 화합물.
제1항에 있어서, 일반식(Ⅰ)에서 라디칼 R6내지 R12중 2개 이상이 수소인 화합물.
제1항에 있어서, 일반식(Ⅰ)에서 R6가 수소, -Cl, -Br 또는 메틸인 화합물.
제1항에 있어서, 일반식(Ⅰ)에서 R9가 수소 또는 -Cl인 화합물.
제1항에 있어서, 일반식(Ⅰ)에서 R11이 수소 또는 -Cl인 화합물.
제1항에 있어서, 일반식(Ⅰ)에서 R10및/또는 R12가 -Cl, -Br, 비치환되거나 치환된 펜옥시 또는 -COO-(C1-C2알킬)인 화합물.
제1항에 있어서, 일반식(Ⅰ)에서, R6가 수소, -Cl, -Br 또는 메틸이거나, R9가 수소 또는 -Cl이거나, R11이 수소 또는 -Cl이거나, R10및/또는 R12가 -Cl, -Br, 비치환되거나 치환된 펜옥시 또는 -COO-(C1-C2알킬)이거나, R7및/또는 R8이 수소, -F, -Cl, -NO2, CF3-, -Br, C1-C4알킬, C1-C4알콕시, 페닐-CO-, α-시아노벤질, C1-C8아실-NR15-, 피릴, -COO-(C1-C12알킬)펜옥시, 또는 비치환 되거나 -F, -CL, C1-C4알콕시, -COOH 또는 -COO-CC1-C12알킬)에 의해 치환된 페닐티오 또는 페닐티오닐이거나, R7또는 R8이 함께이고, R13이 수소 또는 C1-C6알킬인 화합물.
제1항에 있어서, 일반식(Ⅰ)에서 R13이 C1-C4알킬 또는 C1-C8아실, 또는 비치환되거나 F 또는 -COOR14에 의해 치환된 페닐 또는 벤질이고, R14는 수소 또는 C1-C12알킬인 화합물.
제1항에 있어서, 일반식(Ⅰ)에서 R14가 수소, C1-C18알킬, -CnH27-O-mH(여기서, n은 1 내지 6의 정수이고, m은 1 내지 20이다), 페닐, C1-C6알킬페닐, 벤질, C1-C6알킬벤질 또는 사이클로헥실인 화합물.
제1항에 있어서, 일반식(Ⅰ)에서 R15가 수소, C1-C6알킬, 페닐, 벤질이거나 두개의 R15라디칼이 함께 테트타메틸렌, 펜타메틸렌, 3-옥사-1,5-펜틸렌 또는 1,3-부타디엔-1,4-디일인 화합물.
제1항에 있어서, R1내지 R5가 수소이거나, R1,R2,R4및 R5가 수소이고, R3는 -CO2C2H5이며, R6및 R8이 Cl이고, R7및 R9내지 R12가 수소이며 X는 NCH3또는 N-n-C3H7인 화합물.
쌍극성 비양자성 용매 또는 양자성 용매의 존재하에 승온에서 일반식(Ⅱ)화합물을 일반식(Ⅲ)의 화합물과 반응시킴을 특징으로 하여, 제1항에 따른 일반식(Ⅰ)의 화합물을 제조하는 방법.
상기식에서, X 및 R1내지 R12는 제1항에서 정의한 바와 동일하고, Y는 -NO2또는 할로겐이며, M는 알칼리금속 양이온 또는 4급 암모늄 또는 포스포늄 양이온이다.
a)방사선-감지 유기물질 및 b)1-펜옥시-4-메틸크산텐-9-온을 포함하는 제1항에 따른 일반식(Ⅰ)의 화합물 하나 이상을 함유하는 방사선-감지 조성물.
제16항에 있어서, 일반식(Ⅰ)의 화합물이 성분 a)를 기준으로 하여 0.001 내 20중량%의 양으로 존재하는 조성물.
제16항에 있어서, 방사선-감지 유기물질이 a1)광중합성 또는 광이합성 에틸렌계 불포화 그룹을 함유하는 비휘발성 단량체, 올리고머 또는 중합체 물질, a2)양이온-경화가능한 시스템 또는 a3)광가교결합 가능한 폴리이미드인 조성물.
제18항에 있어서, 성분a1)이, 에스테르 그룹이 하기 일반식의 라디칼을 함유하는 아크릴레이트, 메타크릴레이트 또는 말레에이트의 단독중합체 또는 공중합체인 조성물.
상기식에서, A는 비치환되거나 하이드록실-치환된 직쇄 또는 측쇄C1-C12알킬렌, 사이클로헥실렌 또는 페닐렌이고, R20및 R21은 각각 독립적으로 Cl,Br,페닐 또는 C1-C4알킬이거나, 이들은 함께 트리메틸렌, 테트라메틸렌 또는을 나타낸다.
제18항에 있어서, 성분 a2)가, 광개시제가 혼입된, 분자중에 에폭사이드 그룹2개 이상을 함유하는 혼입된 에폭사이드 화합물인 조성물.
무색 유기용매, 중합체 또는 유기 글래스 또는 복합물 글래스, 및 1-펜옥시-4-메틸크산텐-9-온을 포함하는 제1항에 따른 일반식(Ⅰ)의 화합물을 함유하는 조성물.
1-펜옥시-4-메틸크산텐-9-온을 포함하는 제1항에 따른 일반식(Ⅰ)의 화합물을 물질중에 혼입시킨 다음, 이 물질을 광-조사시킴을 특징으로 하여, 광의 작용하에서 착색물질을 제조하는 방법.
1-펜옥시-4-메틸크산텐-9-온을 포함하는 제1항에 따른 일반식(Ⅰ)의 화합물의, 광 작용하에서의 감광제, 색지시제 또는 광개폐성 성분으로서의 용도.
※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019900019252A 1989-11-29 1990-11-27 광색성 화합물,이의 제조방법 및 용도 KR910009688A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CH427089 1989-11-29
CH4270/89-7 1989-11-29

Publications (1)

Publication Number Publication Date
KR910009688A true KR910009688A (ko) 1991-06-28

Family

ID=4272975

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019900019252A KR910009688A (ko) 1989-11-29 1990-11-27 광색성 화합물,이의 제조방법 및 용도

Country Status (5)

Country Link
US (2) US5310909A (ko)
EP (1) EP0430881A3 (ko)
JP (1) JPH03190870A (ko)
KR (1) KR910009688A (ko)
CA (1) CA2030955A1 (ko)

Families Citing this family (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0494048A1 (de) * 1991-01-03 1992-07-08 Ciba-Geigy Ag Photochrome Benzothioxanthonoxide, Verfahren zu deren Herstellung und deren Verwendung
GB9113580D0 (en) 1991-06-24 1991-08-14 Int Bio Synthetics Ltd Thioxanthone derivatives
EP0594538A3 (en) * 1992-10-20 1994-06-29 Ciba Geigy Ag Photochromatic acridone derivatives, process for their preparation and their use
US6025408A (en) * 1997-03-27 2000-02-15 First Chemical Corporation Liquid thioxanthone photoinitiators
US6087102A (en) 1998-01-07 2000-07-11 Clontech Laboratories, Inc. Polymeric arrays and methods for their use in binding assays
US20030180789A1 (en) * 1998-12-30 2003-09-25 Dale Roderic M.K. Arrays with modified oligonucleotide and polynucleotide compositions
US6087112A (en) * 1998-12-30 2000-07-11 Oligos Etc. Inc. Arrays with modified oligonucleotide and polynucleotide compositions
US20030177380A1 (en) * 2002-03-18 2003-09-18 Woods Stanley P. Devices for storing array data and methods of using the same
EP2471924A1 (en) 2004-05-28 2012-07-04 Asuragen, INC. Methods and compositions involving microRNA
KR20130042049A (ko) * 2004-07-14 2013-04-25 아사히 가세이 이-매터리얼즈 가부시키가이샤 감광성 조성물, 패턴형성재료, 감광성 적층체, 및 패턴형성장치 및 패턴형성방법
CA2850323A1 (en) 2004-11-12 2006-12-28 Asuragen, Inc. Methods and compositions involving mirna and mirna inhibitor molecules
EP1869213A4 (en) 2005-03-14 2008-05-14 Univ Leland Stanford Junior METHODS AND COMPOSITIONS FOR ASSESSING THE SURVIVAL OF GRAFFON IN A RECIPIENT OF SOLID MEMBER TRANSPLANTATION
US20060234159A1 (en) * 2005-04-19 2006-10-19 Nitto Denko Corporation Photosensitive epoxy resin adhesive composition and use thereof
EP1731620A1 (en) 2005-06-07 2006-12-13 Institut National De La Sante Et De La Recherche Medicale (Inserm) Method for the diagnosis of immune graft tolerance
US20070202515A1 (en) * 2005-10-12 2007-08-30 Pathologica, Llc. Promac signature application
US20100003189A1 (en) 2006-07-14 2010-01-07 The Regents Of The University Of California Cancer biomarkers and methods of use thereof
CA2664383C (en) 2006-09-19 2017-08-22 Asuragen, Inc. Micrornas differentially expressed in pancreatic diseases and uses thereof
EP2145001A2 (en) 2006-09-19 2010-01-20 Asuragen, Inc. Mir-15, mir-26, mir -31,mir -145, mir-147, mir-188, mir-215, mir-216 mir-331, mmu-mir-292-3p regulated genes and pathways as targets for therapeutic intervention
WO2008095050A1 (en) 2007-01-30 2008-08-07 Pharmacyclics, Inc. Methods for determining cancer resistance to histone deacetylase inhibitors
EP1961825A1 (en) 2007-02-26 2008-08-27 INSERM (Institut National de la Santé et de la Recherche Medicale) Method for predicting the occurrence of metastasis in breast cancer patients
CN101372538B (zh) * 2007-08-21 2012-08-29 北京万和芯源生物技术有限公司 紫外光辅助的表面改性方法及具有由此方法形成的表面的制品
WO2009097424A1 (en) 2008-01-29 2009-08-06 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Fstl-1 as a biomarker of inflammation
US8658379B2 (en) 2008-01-29 2014-02-25 University of Pittsburgh—of the Commonwealth System of Higher Education Follistatin-like protein-1 as a biomarker for sepsis
US8258111B2 (en) 2008-05-08 2012-09-04 The Johns Hopkins University Compositions and methods related to miRNA modulation of neovascularization or angiogenesis
WO2010096036A2 (en) 2008-05-14 2010-08-26 Millennium Pharmaceuticals, Inc. Methods and kits for monitoring the effects of immunomodulators on adaptive immunity
US20110201519A1 (en) 2008-08-18 2011-08-18 Sarwal Minnie M Methods and Compositions for Determining a Graft Tolerant Phenotype in a Subject
EP2615460B1 (en) 2009-08-22 2014-06-25 The Board Of Trustees Of The University Of the Leland Stanford Junior University Imaging and evaluating embryos, oocytes, and stem cells
US9290813B2 (en) 2009-12-02 2016-03-22 The Board Of Trustees Of The Leland Stanford Junior University Biomarkers for determining an allograft tolerant phenotype
GB0922085D0 (en) 2009-12-17 2010-02-03 Cambridge Entpr Ltd Cancer diagnosis and treatment
WO2011108930A1 (en) 2010-03-04 2011-09-09 Interna Technologies Bv A MiRNA MOLECULE DEFINED BY ITS SOURCE AND ITS DIAGNOSTIC AND THERAPEUTIC USES IN DISEASES OR CONDITIONS ASSOCIATED WITH EMT
EP2561092A1 (en) 2010-04-19 2013-02-27 The Procter & Gamble Company Genetic signatures and gene chips associated with administration of electrically conducted radio frequency current to skin and methods and treatments relating thereto
MX2012012236A (es) 2010-04-19 2012-11-23 Procter & Gamble Aplicacion combinada de energia y composicion topica para regular la condicion de la piel de mamiferos.
US20120003639A1 (en) 2010-04-27 2012-01-05 Prelude, Inc. Cancer biomarkers and methods of use thereof
WO2011146725A1 (en) 2010-05-19 2011-11-24 Bayer Healthcare Llc Biomarkers for a multikinase inhibitor
EP2591106A1 (en) 2010-07-06 2013-05-15 InteRNA Technologies B.V. Mirna and its diagnostic and therapeutic uses in diseases or conditions associated with melanoma, or in diseases or conditions associated with activated braf pathway
WO2012019099A2 (en) 2010-08-05 2012-02-09 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Follistatin-like-protein-1 as a biomarker for inflammatory disorders
CN106978480A (zh) 2010-09-15 2017-07-25 阿尔玛克诊断有限公司 用于癌症的分子诊断试验
TWI414520B (zh) * 2010-10-06 2013-11-11 Nat Defense Medical Ct 噻噸酮衍生物
EP2772550B1 (en) 2010-11-17 2017-03-29 Interpace Diagnostics, LLC Mirnas as biomarkers for distinguishing benign from malignant thyroid neoplasms
EP2474617A1 (en) 2011-01-11 2012-07-11 InteRNA Technologies BV Mir for treating neo-angiogenesis
AU2012220540B2 (en) 2011-02-23 2016-11-10 The Board Of Trustees Of The Leland Stanford Junior University Methods of detecting aneuploidy in human embryos
US20140057295A1 (en) 2011-02-28 2014-02-27 Barbara J. Stegmann Anti-mullerian hormone changes in pregnancy and prediction of adverse pregnancy outcomes and gender
US10177312B2 (en) 2011-05-05 2019-01-08 Merck Patent Gmbh Compounds for electronic devices
MX2013014065A (es) 2011-06-02 2014-06-23 Almac Diagnostics Ltd Prueba diagnóstica molecular para el cancer.
US9644241B2 (en) 2011-09-13 2017-05-09 Interpace Diagnostics, Llc Methods and compositions involving miR-135B for distinguishing pancreatic cancer from benign pancreatic disease
US20130157884A1 (en) 2011-10-26 2013-06-20 Asuragen, Inc. Methods and compositions involving mirna expression levels for distinguishing pancreatic cysts
EP2771487A1 (en) 2011-10-27 2014-09-03 Asuragen, INC. Mirnas as diagnostic biomarkers to distinguish benign from malignant thyroid tumors
WO2013063496A1 (en) 2011-10-28 2013-05-02 Millennium Pharmaceuticals, Inc. Biomarkers of response to nae inhibitors
CN104039328B (zh) 2011-11-11 2018-10-09 米伦纽姆医药公司 对蛋白酶体抑制剂的反应的生物标记
US20150184246A1 (en) 2011-11-11 2015-07-02 Millennium Pharmaceuticals, Inc. Biomarkers of response to proteasome inhibitors
WO2013087789A1 (en) 2011-12-13 2013-06-20 Glykos Finland Ltd. Antibody isoform arrays and methods thereof
EP2870263A1 (en) 2012-07-03 2015-05-13 InteRNA Technologies B.V. Diagnostic portfolio and its uses
CN104822844B (zh) 2012-10-01 2019-05-07 米伦纽姆医药公司 预测对抑制剂的反应的生物标记物和方法以及其用途
US20140100124A1 (en) 2012-10-04 2014-04-10 Asuragen, Inc. Diagnostic mirnas for differential diagnosis of incidental pancreatic cystic lesions
SI2925888T1 (en) 2012-11-28 2018-02-28 Merck Sharp & Dohme Corp. Compounds and methods for the treatment of cancer
US11091809B2 (en) 2012-12-03 2021-08-17 Almac Diagnostic Services Limited Molecular diagnostic test for cancer
CA2907377A1 (en) 2013-03-15 2014-09-18 Baylor Research Institute Tissue and blood-based mirna biomarkers for the diagnosis, prognosis and metastasis-predictive potential in colorectal cancer
EP2970909A4 (en) 2013-03-15 2017-02-15 The University of Chicago Methods and compositions related to t-cell activity
US9758835B2 (en) 2013-03-15 2017-09-12 Baylor Research Institute Ulcerative colitis (UC)-associated colorectal neoplasia markers
WO2015094992A1 (en) 2013-12-17 2015-06-25 Merck Sharp & Dohme Corp. Ifn-gamma gene signature biomarkers of tumor response to pd-1 antagonists
GB201409479D0 (en) 2014-05-28 2014-07-09 Almac Diagnostics Ltd Molecular diagnostic test for cancer
EP3194623B1 (en) 2014-08-12 2022-01-05 Wayne State University Systems and methods to detect stem cell stress and uses thereof
EP3227687A4 (en) 2014-12-05 2018-10-24 Prelude, Inc. Dcis recurrence and invasive breast cancer
CN107109700A (zh) 2014-12-09 2017-08-29 默沙东公司 用于推导对pd‑1拮抗剂的反应的基因特征生物标志物的系统和方法
ES2844799T3 (es) 2015-04-17 2021-07-22 Merck Sharp & Dohme Biomarcadores sanguíneos de sensibilidad tumoral a antagonistas de PD-1
GB201512869D0 (en) 2015-07-21 2015-09-02 Almac Diagnostics Ltd Gene signature for minute therapies
US20190128895A1 (en) 2016-04-20 2019-05-02 Ldx Prognostics Limited Co. Methods and compositions for prognosing preterm birth
JP6691617B2 (ja) 2016-05-17 2020-04-28 エルディエックス・プログノスティクス・リミテッド・カンパニーＬｄｘ Ｐｒｏｇｎｏｓｔｉｃｓ Ｌｉｍｉｔｅｄ Ｃｏ． 子癇前症の評価を提供するための方法及び組成物
US10451195B2 (en) 2016-10-25 2019-10-22 International Business Machines Corporation Hose with tunable flexibility using cyclizable, photochromic molecules
BR112019022488A2 (pt) 2017-04-28 2020-06-16 Merck Sharp & Dohme Corp. Biomarcadores para terapêutica do câncer
WO2019086603A1 (en) 2017-11-03 2019-05-09 Interna Technologies B.V. Mirna molecule, equivalent, antagomir, or source thereof for treating and/or diagnosing a condition and/or a disease associated with neuronal deficiency or for neuronal (re)generation
US20200377958A1 (en) 2017-12-01 2020-12-03 Millennium Pharmaceuticals, Inc. Biomarkers and methods for treatment with nae inhibitors
US11957695B2 (en) 2018-04-26 2024-04-16 The Broad Institute, Inc. Methods and compositions targeting glucocorticoid signaling for modulating immune responses
WO2019213660A2 (en) 2018-05-04 2019-11-07 The Broad Institute, Inc. Compositions and methods for modulating cgrp signaling to regulate innate lymphoid cell inflammatory responses
WO2020036926A1 (en) 2018-08-17 2020-02-20 Cellecta, Inc. Multiplex preparation of barcoded gene specific dna fragments
WO2020056338A1 (en) 2018-09-14 2020-03-19 Prelude Corporation Method of selection for treatment of subjects at risk of invasive breast cancer
US20220401460A1 (en) 2018-10-10 2022-12-22 Dana-Farber Cancer Institute, Inc. Modulating resistance to bcl-2 inhibitors
AU2020228047A1 (en) 2019-02-27 2021-09-30 Madera Therapeutics, LLC Use of caseinolytic protease P function as a biomarker of drug response to imipridone-like agents
US20220154282A1 (en) 2019-03-12 2022-05-19 The Broad Institute, Inc. Detection means, compositions and methods for modulating synovial sarcoma cells
EP3937969A1 (en) 2019-03-14 2022-01-19 The Broad Institute, Inc. Compositions and methods for modulating cgrp signaling to regulate intestinal innate lymphoid cells
WO2020191069A1 (en) 2019-03-18 2020-09-24 The Broad Institute, Inc. Modulation of type 2 immunity by targeting clec-2 signaling
EP3942023A1 (en) 2019-03-18 2022-01-26 The Broad Institute, Inc. Compositions and methods for modulating metabolic regulators of t cell pathogenicity
JP2022526844A (ja) 2019-04-12 2022-05-26 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 筋肉量及び酸化的代謝を増加させるための組成物及び方法
US20220282333A1 (en) 2019-08-13 2022-09-08 The General Hospital Corporation Methods for predicting outcomes of checkpoint inhibition and treatment thereof
US11981922B2 (en) 2019-10-03 2024-05-14 Dana-Farber Cancer Institute, Inc. Methods and compositions for the modulation of cell interactions and signaling in the tumor microenvironment
US11793787B2 (en) 2019-10-07 2023-10-24 The Broad Institute, Inc. Methods and compositions for enhancing anti-tumor immunity by targeting steroidogenesis
US11844800B2 (en) 2019-10-30 2023-12-19 Massachusetts Institute Of Technology Methods and compositions for predicting and preventing relapse of acute lymphoblastic leukemia
US20230044602A1 (en) 2019-12-20 2023-02-09 EDWARD Via COLLEGE OF OSTEOPATHIC MEDICINE Cancer signatures, methods of generating cancer signatures, and uses thereof
US20240150453A1 (en) 2021-03-09 2024-05-09 Massachusetts Institute Of Technology Methods of predicting response to anti-tnf blockade in inflammatory bowel disease
CN114149368A (zh) * 2021-11-30 2022-03-08 云南大学 一种有机室温电致磷光材料、制备方法及其有机电致发光二极管
WO2024028794A1 (en) 2022-08-02 2024-02-08 Temple Therapeutics BV Methods for treating endometrial and ovarian hyperproliferative disorders
WO2024124044A1 (en) 2022-12-07 2024-06-13 The Brigham And Women’S Hospital, Inc. Compositions and methods targeting sat1 for enhancing anti¬ tumor immunity during tumor progression

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE919107C (de) * 1940-04-03 1954-10-14 Bayer Ag Verfahren zur Herstellung von Xanthenen oder Thioxanthenen
US3752813A (en) * 1969-06-25 1973-08-14 Merck & Co Inc Ortho hydroxy dihydro phenozine carboxylic acids and derivatives
BE759292A (fr) * 1969-11-27 1971-05-24 Allen & Hanburys Ltd Derives de xanthone, leur preparation et leur emploi
DE2546822A1 (de) * 1975-10-18 1977-04-21 Bayer Ag 4-amino-thioxanthon-s,s-dioxide
CH640849A5 (de) * 1979-05-18 1984-01-31 Ciba Geigy Ag Thioxanthoncarbonsaeureester, -thioester und -amide.
JPS58120605A (ja) * 1982-01-14 1983-07-18 Nippon Kayaku Co Ltd チオキサントンスルホオキシド又はチオキサントンスルホジオキシド誘導体を用いる光重合性樹脂組成物の硬化法
US4585876A (en) * 1982-11-25 1986-04-29 Ciba-Geigy Corporation Novel xanthones and thioxanthones
US4752813A (en) * 1986-08-08 1988-06-21 International Business Machines Corporation Schottky diode and ohmic contact metallurgy

Also Published As

Publication number Publication date
US5432049A (en) 1995-07-11
EP0430881A2 (de) 1991-06-05
EP0430881A3 (en) 1991-10-23
US5310909A (en) 1994-05-10
JPH03190870A (ja) 1991-08-20
CA2030955A1 (en) 1991-05-30

Similar Documents

Publication Publication Date Title
KR910009688A (ko) 광색성 화합물,이의 제조방법 및 용도
DE68906440T2 (de) Polymerbeschichtungen für Wellenleiter aus optischen Fasern.
MX163420B (es) Dispersiones de particulas huecas permeables de base dura o fija
KR830007745A (ko) 폴리우레탄 혼합물의 제조방법
KR940013499A (ko) 푸마길롤 유도체의 제약학적 안정 조성물
KR940006563A (ko) 헤어스프레이 및 이에 사용하기 위한 아크릴 중합체 조성물
AR003526A1 (es) Sistema estabilizador para estabilizar materiales polimeros y metodo para producir un sistema estabilizado en forma de pellets.
EP0172450A2 (de) Flüssigkristalline Phasen aufweisende Polymerzusammensetzungen
US20030100672A1 (en) Method for obtaining a stabilized photochromic latex, latex obtained, and application to ophthalmic optics
DE69718842D1 (de) Sehr hygroskopische Polyamidfasern und Herstellung und Verwendung derselben
EP0882836A3 (de) Verfahren zum Vernetzen von cellulosehaltigen Fasermaterialien
ATE42568T1 (de) Textilweichmacherzusammensetzung.
EP0063684A1 (de) Immersionsöl
EP1171411B1 (en) Process for the preparation of a diol
KR940009166A (ko) 광호변성 화합물, 이의 제조방법 및 용도
PT90125A (pt) Processo para a preparacao de derivados de benzopirano
BR8606427A (pt) Composto,processo para preparar o composto,composicao inseticida e processo de combater pragas de insetos
KR880701233A (ko) 새로운 비페닐 유도체와 그의 제조 방법 및 용도
JPS5575405A (en) Photopolymerizable composition
EP0207287A3 (de) Indolinderivate, Verfahren zu ihrer Herstellung und diese Indolinderivate enthaltende kosmetische Lichtschutzmittel
KR920013028A (ko) 광증감제 조성물
US5274179A (en) Fluorinated photoinitiators and their application in UV curing of fluorinated monomers
KR840004422A (ko) 사이프로헵타딘-3-카복실산의 에스테르 및 관련 화합물의 제조방법
KR880003201A (ko) 플라스틱 클래딩 조성물 및 이로부터 제조된 실리카 또는 글래스 코어 광섬유
DE60016580T2 (de) Verfahren zur herstellung eines diols

Legal Events

Date Code Title Description
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid